LOXO 292 companion diagnostic - Illumina/Loxo Oncology

Drug Profile

LOXO 292 companion diagnostic - Illumina/Loxo Oncology

Alternative Names: LOXO 292 companion diagnostic - Loxo Oncology/Illumina; TruSight™ Tumor 170 LOMO-292 companion diagnostic - Illumina/Loxo Oncology; TruSight™ Tumor 170 LOMO-292 companion diagnostic - Loxo Oncology/Illumina

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Illumina; Loxo Oncology
  • Class Diagnostic agents
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 10 Apr 2018 Illumina and Loxo Oncology agree to co-promote and co-develop LOXO-292 companion diagnostic for Cancer
  • 10 Apr 2018 Early research in Cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top